BiQ Journal: Taking a Look at Cosmo Pharmaceutical 04/06/26
While I try to share a lot of information with BiQ members via the BiQ Chat forum, I haven't written a formal article about new names on my radar in a while. After spending considerable time researching Cosmo Pharmaceutical (CMOPF), I thought the company was well-deserving of a longer-form article.
Cosmo Pharmaceutical is headquartered in Dublin, Ireland, and its manufacturing & research hub is based in Italy. The company trades on the SIX under the ticker COPN. In the US, foreign shares are available via the symbol CMOPF. As far as I know, the company has no US listing and does not offer ADRs.
Cosmo first appeared on my radar when I read a blurb about Winlevi, its 1% Clascoterone formulation for the treatment of acne vulgaris. Currently, Winlevi is the first and only topical androgen receptor inhibitor approved for this indication, which allows it to treat the hormonal drivers of acne via topical administration with no systemic absorption.
While Winlevi is somewhat interesting, and the upcoming global expansion will provide a tailwind for broader adoption, I don't see it as an "attractive enough" long-term value driver on its own. Although Winlevi is currently the market leader in this space, significant incoming competition could challenge it across efficacy, safety, and convenience. Winlevi caught my initial interest; however, upon further examination, it wasn't compelling enough on its own to form the basis of an investment thesis.
What my research led to, however, was a deeper interest in Cosmo's two other late-stage and commercial assets: Breezula (5% Clascoterone formulation for treating male hair loss) and GI Genius.
Cosmo is an interesting company. It's part R&D firm, part CDMO, part pharma, and part medtech. For obvious reasons, I couldn't resist diving deeper. However, in the interest of keeping this article to an acceptable length, I will focus on the two most exciting assets I mentioned above: Breezula and GI Genius.
Breezula is a 5% Clascoterone formulation, which Cosmo is developing for the treatment of hair loss in men. Breezula acts as a topical DHT blocker, similar in some ways to topical Finasteride. The main advantage, and key differentiator, for Breezula is safety. Unlike Finasteride, Breezula has no systemic impact, as the drug is designed to break down immediately upon entering the bloodstream. The recent P3 trial demonstrated a pristine safety profile with no sexual side effects, no HPA axis suppression (i.e. no systemic hormone disruption), and mild TEAEs, including pruritus, erythema, and skin flaking, all at less than 2%.
As for efficacy, Breezula demonstrated regrowth of around 10-13 hairs/cm2 vs 15-18hairs/cm2 for topical Finasteride. However, I think Breezula's pristine safety profile is a key differentiator. Despite its efficacy, many men avoid Finasteride due to the potential for negative effects on libido, mood, brain fog, and exposure risk for women who are pregnant or trying to conceive. Breezula eliminates these concerns, potentially offering nearly on-par efficacy with a clean safety profile
While Breezula could be positioned as a stand-alone treatment option, I would imagine it would also be marketed as a combination therapy with Minoxidil. This combination would offer synergistic effects that both block DHT, the root cause of androgenic male hair loss, and help to increase blood flow and circulation to promote healthier follicles.
According to Cosmo's market research, Breezula represents a $20B opportunity in the US, and up to $27B worldwide. Surveys conducted by the company indicated that at a $225 monthly price, 85% of surveyed men were likely or very likely to try the product, and 75% would be open to using telehealth platforms to access it.
After the recent release of 6-month P3 data, the company is currently awaiting 12-month safety and durability data, expected by this Spring. Management has announced that the company is in serious partnership negotiations with several large pharmaceutical companies, and if 12-month data confirm the earlier P3 results with no new safety signals, I expect a partnership agreement could be announced soon thereafter. I see a global partnership for Breezula as being a transformative event for the company.
While this is purely speculative on my part, one thing that nobody seems to be discussing is the potential for Breezula to secure an OTC label in the future, given its clean safety profile. In my opinion, winning an OTC label could potentially double the TAM. In fact, if the clinical data continues to hold up, Breezula could be an even safer drug than topical Minoxidil, which, unlike Breezula, is associated with a low level of heart/BP risk.
The ACNU (Additional Condition for Nonprescription Use) Rule, which went into effect in May 2025, allows the FDA to approve an RX-to-OTC switch if the manufacturer includes a "digital condition", such as a mandatory mobile app questionnaire or QR-code-based screening tool. Interestingly enough, Cosmo is developing just such an AI-based companion app, which it plans to launch concurrently with Breezula and make available for free. While I'm not suggesting the motivation behind this app is to facilitate an RX-to-OTC switch, I think the possibility is enticing.
Although Breezula represents a very exciting opportunity for the company and its investors, I think GI Genius could be equally, if not even more, transformative, as I will discuss below.